Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)
CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study...
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 31, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
Progress has been achieved in the pilot construction of the micro-application cluster for the State Grid power distribution network in Xinjiang
URUMQI, China, March 27, 2025 /PRNewswire/ -- On March 25, State Grid Xinjiang Electric Power Co., Ltd. successfully completed the deployment and testing of the distribution network micro-application cluster, marking a phased advancement in the...
Keymed Biosciences Announces Annual Results of 2024
CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα...
Waterdrop Inc. Receives a 'Buy' Rating from UOB Kay Hian with Price Target of US$2.20
BEIJING, March 19, 2025 /PRNewswire/ -- On March 14, 2025, UOB Kay Hian included Waterdrop Inc. (WDH) for the first time in its most recent report, commenting that the company has built a substantial user base through its strong brand equity and is...
VINSSEN Acquires AIP Certification for Korea's First Hydrogen Propulsion Tugboat
SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- VINSSEN, maritime decarbonization technology specialist focused on hydrogen fuel cells and supporting systems, has received the Approval in Principle (AIP) certification from the Korean Register for...
Palace Museum bridging civilizations
BEIJING, March 14, 2025 /PRNewswire/ -- A news report from chinadaily.com.cn： The Palace Museum in Beijing, which was called the Forbidden City, is an important repository of China's 5,000-year-old civilization and traditional Chinese culture. The...
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple...
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases
Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis Interim safety and pharmacokinetic data from healthy volunteers anticipated in 2H...
State Grid Xinjiang Information & Telecommunication Company: Successful Deployment and Upgrade of the Artificial Intelligence Large Model Platform
ÜRÜMQI, China, Feb. 21, 2025 /PRNewswire/ -- On February 10, 2024, State Grid Xinjiang Information & Telecommunication Company successfully completed the comprehensive deployment and joint verification of the artificial intelligence large model...